The Federal Circuit affirmed the TTAB’s refusal to register EVERYBODY VS. RACISM as a trademark for apparel, holding that the phrase functions as an informational, anti-racist message rather than as a source identifier — and confirming that widespread use of a phrase in an informational contex
The Federal Circuit affirmed the ITC’s finding that Universal Electronics satisfied the domestic industry requirement under Section 337 based on its investments in QuickSet technology — a patented component integrated into televisions — even though those investments did not cover the entire te
The Federal Circuit held that the statutory prohibition barring time-barred, joined IPR parties from introducing new issues into a proceeding does not apply when a patent owner files a motion to amend its claims—a joined party may oppose such a motion even if it could not have raised new issues in t
The Federal Circuit affirmed that a settlement agreement’s forum selection clause requiring patent disputes to be filed in Delaware federal court did not bar Abbott from filing inter partes review petitions after the agreement’s covenant-not-to-challenge period expired—because the agreem
The Federal Circuit affirmed the PTAB’s claim construction of ‘storage element’ based on inventor lexicography in an incorporated-by-reference patent, holding that the PTAB is not bound by a conflicting district court construction and that Intel’s reply arguments were proper
The Federal Circuit affirmed that generic drug manufacturers who carve out patented indications from their drug labels—the so-called ‘skinny label’ strategy—do not infringe method-of-use patents covering those omitted indications under the Hatch-Waxman Act, and that brand-name companies
The Federal Circuit affirmed that the PTAB retains authority to issue a final written decision in an IPR or PGR even after the statutory one-year (plus extension) deadline has passed, provided no clear contrary congressional intent bars the late decision.
The Federal Circuit affirmed the PTAB’s ruling that Medtronic failed to prove Teleflex’s guide extension catheter patents unpatentable, finding that the claimed invention was conceived and reduced to practice before the critical date of the asserted prior art.
The Federal Circuit dismissed Allgenesis’s appeal from an adverse IPR decision for lack of Article III standing, holding that vague future product plans and non-appealable priority rulings do not constitute a concrete injury sufficient to invoke federal court jurisdiction.
The Federal Circuit vacated an infringement judgment in an ANDA case involving pulmonary hypertension drug patents, holding that the district court erred by construing ‘a pH of 13’ based solely on intrinsic evidence when the parties submitted competing extrinsic evidence—including textbo